AKT1 and hepatocellular carcinoma: Therefore, these pathways above showed the potential pharmacological mechanisms of lenvatinib treating HCC, implying that the processes of bile secretion, MAPK signaling pathway, cGMP-PKG signaling pathway, PI3K-Akt signaling pathway, and Ras signaling pathway can be designed as underlying drug targeting pathways for the suppression of HCC in the future.